Vertex Announces U.S. FDA Approval for KALYDECO^® (Ivacaftor) To Treat Eligible Infants With CF Ages 1 Month and Older

Vertex Pharmaceuticals, Inc. announced the US FDA approved KALYDECO® for use in children with cystic fibrosis (CF) who have at least one mutation in their cystic fibrosis transmembrane conductance regulator gene that was responsive to the treatment based on clinical and/or in vitro assay data.